CamilleLuciaBedrosianMD

Oncology • Cambridge, MA

Physician

Join to view full profile

Are you Dr. Bedrosian?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 52 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
26 Landsdowne Street
Cambridge, MA 02139
Phone+1 617-494-0400

Fax+1 617-494-8144

Summary

Dr. Camille Bedrosian, MD is an oncologist in Cambridge, Massachusetts. She is currently licensed to practice medicine in Massachusetts and North Carolina.

Education & Training

Duke University HospitalFellowship, Hematology and Medical Oncology, 1986 - 1988
Duke University HospitalResidency, Internal Medicine, 1984 - 1986
Newton-Wellesley HospitalInternship, Internal Medicine, 1983 - 1984
Harvard Medical SchoolClass of 1983

Certifications & Licensure

MA State Medical License 1998 - 2026
NC State Medical License 1987 - 2025
American Board of Internal Medicine Internal Medicine

Publications & Presentations

PubMed

1 citations
Clinical trial data available for UX001, aceneuramic acid extended-release
Camille L. Bedrosian
Journal of the Neurological Sciences. 2020-04-15
57 citations
Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200
Daruka Mahadevan, Mark C. Lanasa, Charles M. Farber, Manjari Pandey, Maria Whelden
Journal for Immunotherapy of Cancer. 2019-08-23
149 citations
Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis
Gérard Socié, Marie-Pierre Caby-Tosi, Jing L. Marantz, Alexander Cole, Camille L. Bedrosian
British Journal of Haematology. 2019-04-01

Press Mentions

Amylyx Touts ‘Encouraging’ Phase 2 Alzheimer’s Trial DataAugust 15th, 2024
Amylyx Pharmaceuticals Announces Publication of Data Showing the Encouraging Effects of AMX0035 on Cerebrospinal Fluid Biomarkers of Core Alzheimer’s Disease Pathology and NeurodegenerationAugust 12th, 2024
Three Misconceptions About the Accelerated Drug Approval PathwayMay 10th, 2023
Join now to see all